Since the objective response rate of immunotherapy in most cancers is still relatively low (46–48), identifying reliable biomarkers from immune cells, such as the percentage of CD8+ cells and TLS structure, to quantify the TME associated with immunotherapy response, is still an emerging area of oncology research (33, 40, 62). The gene discussed is CD8A; the disease is cancer.